SEC filing · 10-K

Quanome Technologies, Inc.: Annual report

Quanome Technologies grew pharmaceutical revenue in fiscal 2026 but posted a wider net loss due to surging operating costs, a supplier write-off, and loan credit loss provisions.

Filed September 25, 2026 · period ended June 30, 2026

Mixed for the company

What the numbers say

Revenue fell 67% to $5.9M versus the prior year; operating margin narrowed from -8.4% to -174.2%; diluted EPS -$0.36 versus -$0.69; operating cash flow -$3.2M (a year earlier -$2.7M); free cash flow -$3.2M (a year earlier -$2.7M); cash fell by $4.1M to $670.3K; diluted share count up 240% (dilution).

Compared with the same period a year earlier, from the figures Quanome Technologies, Inc. reported to the SEC.

What happened

Revenue from continuing pharmaceutical distribution rose 111.8% to $5,850,681, driven by higher infusion product sales and a full year of operations.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Quanome Technologies, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.